Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure

checkorphan
Learn more about:
Patent ductus arteriosus
Related Clinical Trial
Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Aminoglycosides and Duct Radiation-Free Heart Catheterization Using MRI Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability The Pharmacology and Hemodynamics of Dexmedetomidine in Children With Congenital Heart Disease The Preterm Infants’ Paracetamol Study Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants Evaluation of the Brain and Renal Regional Oxygenation Using NIRS in Preterm Infants Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD Hyperion™ International Registry Trial NIRS in PDA VLBW Infants Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance Comparison of Oral and Intravenous Ibuprofen for PDA Treatment in Premature Infants The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants Lifetech CeraFlex™ Post-Market Surveillance Study Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications Nit-Occlud PDA Post-Approval Study Ibuprofen and Renal Function in Premature Infants A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation Canadian National PDA Treatment Study Long Term Results of 450 Percutaneous Closures of PDA in a Single Center Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants AMPLATZER Duct Occluder II Additional Sizes A NEW SCORING SYSTEM FOR PREDICTION OF PDA Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis Feeding During Ibuprofen or Indomethacin Treatment of Preterm Infants The Efficacy of Implementing a Treatment Algorithm in Managing Patent Ductus Arteriosus (PDA) in the Extremely Low Birth Weight Neonatal Population. Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA) Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA Addition of Acetaminophen in Standard PDA Management Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA) Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates Paracetamol Versus Ibuprofen for PDA Closure Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA Timing for the Medical Treatment of Patent Ductus Arteriosus in Preterm Infants Early Treatment Versus Expectative Management of PDA in Preterm Infants International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants Do Elevated BNP Levels Predict Hemodynamically Significant PDAs The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants Brain, Gut and Kidney Blood Flow During Medical Closure of PDA Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term AMPLATZER Duct Occluder II Clinical Study The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth Paracetamol and Patent Ductus Arteriosus (PDA) Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure Pocket Echocardiography System (PES) for Detection of PDA in Neonates Treating the Resistant Patent Ductus Arteriosus (PDA) Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus IV Acetaminophen and Patent Ductus Arteriosus Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI) Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants Patent Ductus Arteriosus and Splanchnic Oxygenation at First Feed Preliminary Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low-weight Infants Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus. Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus

Brief Title

Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure

Official Title

Early vs. Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure and Pain/Stress Reduction

Brief Summary

      The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early
      vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a
      higher PDA closure rate than later use of Ibu. Early use is defined as medication given
      before the infant reaches 96 hrs old. Late use is defined as medication given when infant is
      more than 96 hrs old.

Detailed Description

      Infants with birth weight at <1200gm and/or <28 weeks gestation who have been diagnosed with
      a Patent Ductus Arteriosus (PDA) qualify for the study if there are no contraindications to
      treatment. Infants are randomized into treatment arms of <96 hrs old and >96 hrs old.
      Ibuprofen is given in the dosage of 10 mg/kg on initial dose, followed 24 hours later by 5
      mg/kg dose and then 24 hours later another dose of 5 mg/kg. An echocardiogram will be done
      prior to treatment and then within 48 hours after treatment.

Study Type

Interventional

Primary Outcome

Number of PDA Closures Related to Treatment With Ibuprofen

Secondary Outcome

 Plasma Catecholamines, Glucose, and Lactate Levels 1 and 6 Hours After Ibuprofen Administration

Condition

Patent Ductus Arteriosus

Intervention

Ibuprofen

Study Arms / Comparison Groups

 Early treatment
Description:  Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

15

Start Date

January 2009

Completion Date

November 2011

Primary Completion Date

November 2011

Eligibility Criteria

        Inclusion Criteria:

          -  Birth weight less than 1200gm

          -  Less than 28 weeks gestational age

          -  Confirmed Patent Ductus Arteriosus (PDA) via echocardiogram and clinical exam

        Exclusion Criteria:

          -  Active Bleeding

          -  Currently being treated for Persistent Pulmonary Hypertension (PPHN)

          -  Cardiac anomalies

          -  Chromosomal abnormalities

          -  Endocrine, metabolic, renal, or hepatic disorders

Gender

All

Ages

N/A - 96 Hours

Accepts Healthy Volunteers

No

Contacts

Gary Chan, MD, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT00833365

Organization ID

31394

Responsible Party

Sponsor

Study Sponsor

University of Utah

Collaborators

 H. Lundbeck A/S

Study Sponsor

Gary Chan, MD, Principal Investigator, University of Utah

Verification Date

December 2014